Suturable DuraGen™ PMCF Study

NCT04923867 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2025-04-06

No results posted yet for this study

Summary

The primary goal of this study is to retrospectively collect data on the safety and efficacy of Suturable DuraGen™.

Conditions

  • Cerebrospinal Fluid Leak

Interventions

DEVICE

Suturable DuraGen™

Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.

Sponsors & Collaborators

  • Integra LifeSciences Corporation

    lead INDUSTRY

Principal Investigators

  • Andrew Tummon · Integra LifeSciences

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2024-07-31
Completion
2024-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04923867 on ClinicalTrials.gov